

## Alberta Drug Benefit List (ADBL) interim update now available online

Please be advised that the **June 1, 2024** updates to the ADBL have been posted online at [ab.bluecross.ca/dbl/publications.php](https://ab.bluecross.ca/dbl/publications.php).

Please refer to the **June 1, 2024** updates for complete listings of products available by special authorization, restricted benefits, added products, least cost alternative price changes, products with a price change and discontinued products.

Please note that the online *interactive Drug Benefit List (iDBL)* at [ab.bluecross.ca/dbl/idbl\\_main1.php](https://ab.bluecross.ca/dbl/idbl_main1.php) is a near real-time application, and as such, contains the most up-to-date information.

### Maximum Allowable Cost (MAC) pricing reminder for diclofenac under Alberta government sponsored drug programs

The below products are currently included in a MAC grouping under the Alberta government sponsored drug programs and will have a price increase effective **June 1, 2024**. As a result of the price increase, plan members choosing these products may notice an increase in copay.

DIN	Product description
00002091194	Apo-Diclo SR 100 mg Sustained-Release Tablet
00002261944	Sandoz Diclofenac SR 100 mg Extended-Release Tablet

Prescribers may continue to prescribe and/or plan members may continue to choose any brand name or generic product; however, Alberta government sponsored drug programs will only pay up to the MAC price for each grouping and the plan member will be responsible for paying the difference if the chosen product is priced higher than the applicable MAC price.

For a full listing of prices, please refer to the **June 1, 2024** updates to the ADBL available online at [ab.bluecross.ca/dbl/publications.php](https://ab.bluecross.ca/dbl/publications.php) or the online *iDBL* at [ab.bluecross.ca/dbl/idbl\\_main1.php](https://ab.bluecross.ca/dbl/idbl_main1.php).

*continued next page*

continued from previous page

### Removal of temporary benefits from the ADBL

Due to the shortages of Auro-Galantamine 8 mg Extended-Release Capsule (DIN 02425157), Galantamine ER 8 mg Extended-Release Capsule (DIN 02443015) manufactured by Sanis Health Inc., Mylan-Galantamine ER 8 mg Extended-Release Capsule (DIN 02339439), Auro-Galantamine 16 mg Extended-Release Capsule (DIN 02425165), Galantamine 16 mg Extended-Release Capsule (DIN 02443023) manufactured by Sanis Health Inc., and Mylan-Galantamine 16 mg Extended-Release Capsule (DIN 02339447), **Pat-Galantamine ER 8 mg Extended-Release Capsule (DIN 02316943)** and **Pat-Galantamine ER 16 mg Extended-Release Capsule (DIN 02316951)** were added as temporary benefits for the ADBL.

Alberta Blue Cross has confirmed that the shortage for Auro-Galantamine 8 mg Extended-Release Capsule (DIN 02425157), Mylan-Galantamine ER 8 mg Extended-Release Capsule (DIN 02339439), Auro-Galantamine 16 mg Extended-Release Capsule (DIN 02425165), Galantamine 16 mg Extended-Release Capsule (DIN 02443023), and Mylan-Galantamine 16 mg Extended-Release Capsule (DIN 02339447) have been resolved.

**Pat-Galantamine ER 8 mg Extended-Release Capsule (DIN 02316943)** and **Pat-Galantamine ER 16 mg Extended-Release Capsule (DIN 02316951)** will no longer be considered a temporary benefit for the ADBL after June 8, 2024.

Due to the shortages of Mylan-Nitro 0.4 mg/dose Sublingual Spray (DIN 02243588), Rho-Nitro Pumpspray 0.4 mg/dose Sublingual Spray (DIN 02238998) manufactured by Sandoz Canada Inc., and Nitrolingual Pumpspray 0.4 mg/dose Sublingual Spray (DIN 02231441) manufactured by Sanofi Aventis, **Nitroglycerin Spray 0.4 mg/dose Sublingual Spray (PIN 09858317)** was added as temporary benefit for the ADBL.

Alberta Blue Cross has confirmed that the shortage for Rho-Nitro Pumpspray 0.4 mg/dose Sublingual Spray (DIN 02238998) manufactured by Sandoz Canada Inc. has been resolved.

**Nitroglycerin Spray 0.4 mg/dose Sublingual Spray (PIN 09858317)** will no longer be considered a temporary benefit for the ADBL after June 10, 2024.

Due to the shortage of specialized infant formulas in Canada, **UK-labelled Alfamino Infant Formula Powder (PIN 00999298)** manufactured by Nestle Canada was added as a temporary benefit for the ADBL.

Alberta Blue Cross has confirmed that the shortage of Neocate with DHA & ARA Oral Infant Formula (PIN 00999568) manufactured by Nutricia North America and Puramino A+ Infant Formula Powder (PIN 00999543) manufactured by Mead Johnson Nutrition (Canada) Co. has been resolved.

**UK-labelled Alfamino Infant Formula Powder (PIN 00999298)** will no longer be considered a temporary benefit for the ADBL after June 10, 2024.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit [ab.bluecross.ca/providers/pharmacy-home.php](https://ab.bluecross.ca/providers/pharmacy-home.php)

